Assessment of Pathologic Complete Response of Breast Cancer with Different Molecular Subtypes after Neoadjuvant Chemotherapy with Dynamic Contrast-enhanced MR Imaging
Yuan Jiang 1 , Naishan Qin 1 , Xiaoying Wang 1 , and Li Guo 1
Radiology Department, Peking University
First Hospital, Beijing, Beijing, China
Different molecular subtypes of breast cancer respond
differently to neoadjuvant chemotherapy. Patients who
achieve pathologic complete response (pCR) have better
prognosis than non-pCR. In our study, semi-quantitative
analysis of dynamic contrast-enhanced (DCE) MR Imaging
between pCR and non-pCR was performed in four types of
breast cancer (Luminal A, Luminal B, HER2+ and Triples
negative), and our results showed that DCE-MR Imaging
could become the potential predictor of pCR to NAC in
breast cancer with Luminal B and Triples negative types.
Maybe further study should be performed based on
molecular subtypes of breast cancer.
This abstract and the presentation materials are available to members only;
a login is required.